What is Stat?
STAT delivers trusted and authoritative journalism about health, medicine, and the life sciences. Millions of new readers turned to the company as it sounded the alarm early on about the Covid-19 pandemic. The company's journalists go deep in tough-minded coverage of the business of making medicines, health tech, science, and public health. STAT takes readers inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling roiling battles for talent, money, and market share. The company examines controversies and punctures hype. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life science industry and a revolution in human health.
How much funding has Stat raised?
Stat has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2024): $350K with participation from UMB
Key Investors in Stat
UMB
UMB is a financial institution that has provided debt financing to Stat. This indicates a focus on supporting the company's operational and growth initiatives through credit facilities.
What's next for Stat?
The recent strategic investment signals a new phase of growth and expansion for Stat, likely enabling the company to deepen its investigative journalism, broaden its coverage areas, and enhance its digital platforms. As a key player in the health and life sciences news sector, this backing will empower Stat to continue its mission of providing indispensable insights and exclusive stories, further solidifying its position as a leading source of information in a rapidly evolving industry. The company's ability to attract significant capital in a large-scale, late-stage funding round highlights investor confidence in its business model and its vital contribution to public understanding of complex health and science issues.
See full Stat company page
